

Review of: "Efficacy and Safety of External Extracorporeal Counterpulsation in Heart Failure with Preserved Ejection Fraction"

1

1 First Affiliated Hospital of Chongqing Medical University

Potential competing interests: No potential competing interests to declare.

This review study demonstrated the therapeutic potential of External Extracorporeal Counterpulsation (EECP) in Ejection Fraction (HFpEF) patients. However, in June 2002, the FDA already approved EECP therapy for heart failure patients.

Most references cited by the study regarding EECP in heart failure were published before 2010, but the treatments changed significantly. The updated evidence in this study is absent. The role of EECP in HFpEF in contemporary studies needs to be evaluated under the guideline-recommended combination therapy, including MRA, ARNI, and SGLT2i. Therefore, the paper is not acceptable for publication in Qeios.